FT576 in Subjects With Multiple Myeloma

NCT05182073 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Myeloma

Interventions

DRUG: FT576 (Allogenic CAR NK cells with BCMA expression)
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Daratumumab
DRUG: Bendamustine

Sponsor

Fate Therapeutics